Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2007;49:1291-1297
Published online before print April 23, 2007, doi: 10.1161/HYPERTENSIONAHA.106.085498
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
49/6/1291    most recent
HYPERTENSIONAHA.106.085498v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, Y.
Right arrow Articles by Staessen, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, Y.
Right arrow Articles by Staessen, J. A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-TRYPTOPHAN
*GLYCINE
Related Collections
Right arrow Clinical genetics
Right arrow Risk Factors
Right arrow Epidemiology

(Hypertension. 2007;49:1291.)
© 2007 American Heart Association, Inc.


Original Articles

Angiotensin-Converting Enzyme I/D and {alpha}-Adducin Gly460Trp Polymorphisms

From Angiotensin-Converting Enzyme Activity to Cardiovascular Outcome

Yan Li; Laura Zagato; Tatiana Kuznetsova; Grazia Tripodi; Gianpaolo Zerbini; Tom Richart; Lutgarde Thijs; Paolo Manunta; Ji-Guang Wang; Giuseppe Bianchi; Jan A. Staessen

From the Studies Coordinating Centre (Y.L., T.K., T.R., L.T., J.A.S.), Division of Hypertension and Cardiovascular Research, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium; Divisione di Nefrologia Dialisi e Ipertensione (L.Z., G.Z., P.M., G.B.), Ospedale San Raffaele, Dipartimento di Scienze e Technologie Biomediche, Universitá Vita Salute, Milan, Italy; Prassis Sigma-Tau Research Institute (G.T.), Settimo Milanese, Milan, Italy; and the Centre for Epidemiological Studies and Clinical Trials (Y.L., J-G.W.), Ruijin Hospital, Shanghai Institute of Hypertension, Shanghai Jiaotong University Medical School, Shanghai, People’s Republic of China.

Correspondence to Jan A. Staessen, Studies Coordinating Centre, Laboratory of Hypertension, Campus Gasthuisberg, Herestraat 49, Box 702, B-3000 Leuven, Belgium. E-mail jan.staessen{at}med.kuleuven.be

The angiotensin-converting enzyme (ACE) I/D and the {alpha}-adducin (ADD1) Gly460Trp polymorphisms are associated with cardiovascular risk factors. In a prospective population study and in cell models, we investigated the combined effects of these 2 polymorphisms. We randomly recruited 1287 white subjects (women: 50.0%; mean age: 55.9 years). We obtained outcomes from registries and repeat examinations (median 3). Over 9.0 years (median), 178 fatal or nonfatal cardiovascular events occurred. In ADD1 Trp allele carriers, the multivariate-adjusted hazard ratios associated with ACE DD versus I were 1.72 (P=0.007) for total mortality, 2.35 (P=0.02) for cardiovascular mortality, 2.02 (P=0.005) for all cardiovascular events, and 2.59 (P=0.03) for heart failure. In contrast, these hazard ratios did not reach significance in ADD1 GlyGly homozygotes (0.08≤P≤0.90). The positive predictive value and attributable risk associated with ACE DD homozygosity combined with mutated ADD1 were 36.2% and 10.3%, respectively. To clarify our epidemiological observations, we investigated the effects of mutated human ADD1 on the membrane-bound ACE activity in fibroblasts from 51 volunteers and in transfected human embryonic kidney cells (31 experiments). In fibroblasts (5.10 versus 3.63 nanomoles of generated hippuric acid per milligram of protein per minute; P=0.0021) and human embryonic kidney cells (1.086 versus 0.081 nmol/mg per minute; P=0.017), the membrane-bound ACE activity increased in the presence but not absence of the ADD1 Trp allele. In conclusion, the combination of ACE DD homozygosity and mutated ADD1 worsened cardiovascular prognosis to a similar extent as classic risk factors, possibly because of increased membrane-bound ACE activity in subjects carrying the ADD1 Trp allele.


Key Words: adducin • angiotensin-converting enzyme • clinical genetics • epidemiology • risk factors




This article has been cited by other articles:


Home page
Circ Heart FailHome page
T. Kuznetsova, L. Herbots, B. Lopez, Y. Jin, T. Richart, L. Thijs, A. Gonzalez, M.-C. Herregods, R. H. Fagard, J. Diez, et al.
Prevalence of Left Ventricular Diastolic Dysfunction in a General Population
Circ Heart Fail, March 1, 2009; 2(2): 105 - 112.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. Manunta, G. Lavery, C. Lanzani, P. S. Braund, M. Simonini, C. Bodycote, L. Zagato, S. Delli Carpini, C. Tantardini, E. Brioni, et al.
Physiological Interaction Between {alpha}-Adducin and WNK1-NEDD4L Pathways on Sodium-Related Blood Pressure Regulation
Hypertension, August 1, 2008; 52(2): 366 - 372.
[Abstract] [Full Text] [PDF]